Hong Kong Pharma Digital Technology Holdings Business Summary

Cellyan Biotechnology Co., Ltd, formerly known as Hong Kong Pharma Digital Technology Holdings Ltd (HKPD), operates a dual-segment business model focused on the cross-border over-the-counter (OTC) pharmaceutical market between Hong Kong and Mainland China. The company generates revenue through service fees in its Supply Chain Services division, managed by its subsidiary Joint Cross Border, which provides end-to-end solutions including product enlisting with the Hong Kong Department of Health, customs clearance, and third-party logistics for e-commerce merchants. Its second primary segment, Procurement and Distribution, operated via V-Alliance, earns transaction-based revenue by sourcing and distributing overseas OTC medications to Chinese e-commerce platforms and pharmaceutical distributors. Positioned as a dominant niche player, the company was ranked first by revenue in the third-party OTC cross-border supply chain sector in 2022, competing directly with regional logistics and healthcare providers such as Jayud Global Logistics, New Century Logistics, and PS International Group. The leadership team is anchored by Chief Executive Officer and Director Chenyu Liang, who oversees the firm’s strategic transition following its January 2025 Nasdaq IPO. Chairman and Executive Director Lap Sun Wong, a key figure in the company’s 2016 founding, provides deep institutional knowledge of the Hong Kong pharmaceutical regulatory landscape. The executive suite is further supported by Chief Financial Officer Shu Liu and Chief Strategy Officer Zifeng Wang, both of whom bring extensive experience in cross-border trade and capital markets. The company’s board includes notable independent directors such as Dr. Kam Leung Chan and Mike Yao Zhou, with institutional backing from investors and underwriters including Eddid Securities and Bancroft Capital, reflecting a pedigree rooted in both traditional pharmaceutical logistics and modern digital healthcare integration.